Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial

Confirmed partial response at 220 mg indicates anti-tumor activity of APR-1051 in biomarker-defined cancersEarly clinical data suggest the ...

Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement

Funding will support ongoing development of APR-1051, including expansion into selected patient populations where WEE1 mechanism is well suitedDOYLESTOWN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Aprea ...
The Bakersfield Californian

Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, ...

Confirmed partial response at 220 mg indicates anti-tumor activity of APR-1051 in biomarker-defined cancersEarly clinical data suggest the potential of APR-1051 as a best-in-class WEE1 inhibitorEmergi ...
Seeking Alpha

Zentalis: Leading WEE1 Developer After AstraZeneca's Exit

Zentalis Pharma has shelved its oral SERD and EGFR inhibitors due to competition and focused on ZN-c3, an inhibitor of WEE1. AZN left the WEE1 space last year, which is a cause for both worry and ...
ascopubs.org

Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma

Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331 Uterine serous carcinoma (USC) is a distinct ...
Taiwan News

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an ...
Yahoo Finance

Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial

DOYLESTOWN, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies that ...
Business Wire

Schrödinger To Present New Preclinical Data From Its Wee1 Inhibitor Program At AACR Annual Meeting 2022

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that new ...
Business Insider

Impact Therapeutics Announced First-Patient-Dose of Wee1 Inhibitor IMP7068 in the U.S.

SHANGHAI, March 10, 2021 /PRNewswire/ -- Impact Therapeutics announced today that the first patient was recently dosed in the first-in-human Phase 1 clinical study of Wee1 Inhibitor IMP7068 in the ...
ascopubs.org

Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer

Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts Thirty-four patients with locally advanced ...
Business Wire

Repare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer

MONTREAL & LAUSANNE, Switzerland--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that it has ...